Document Classification

Section Type: RESULTS

Text: We did not detect any significant differences between tenecteplase and placebo in the primary end point of 30-day survival (14. 7 % vs. 17. 0 % ; P = 0. 36 ; relative risk, 0. 87 ; 95 % confidence interval, 0. 65 to 1. 15) or in the secondary end points of hospital admission (53. 5 % vs. 55. 0 %, P = 0. 67), return of spontaneous circulation (55. 0 % vs. 54. 6 %, P = 0. 96), 24-hour survival (30. 6 % vs. 33. 3 %, P = 0. 39), survival to hospital discharge (15. 1 % vs. 17. 5 %, P = 0. 33), or neurologic outcome (P = 0. 69).